Co-Diagnostics (NASDAQ:CODX – Get Free Report) had its price target cut by research analysts at HC Wainwright from $2.00 to $1.50 in a note issued to investors on Monday, Benzinga reports. The brokerage currently has a “neutral” rating on the stock. HC Wainwright’s price target would suggest a potential upside of 31.58% from the company’s current price.
Co-Diagnostics Stock Up 1.8 %
CODX stock traded up $0.02 during trading on Monday, hitting $1.14. The company had a trading volume of 7,983 shares, compared to its average volume of 91,192. The stock has a market cap of $35.66 million, a price-to-earnings ratio of -0.87 and a beta of -0.82. The firm has a 50-day moving average price of $1.27 and a 200-day moving average price of $1.20. Co-Diagnostics has a 12 month low of $0.98 and a 12 month high of $1.73.
Co-Diagnostics (NASDAQ:CODX – Get Free Report) last released its earnings results on Thursday, May 9th. The company reported ($0.31) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.10). The firm had revenue of $0.47 million for the quarter, compared to the consensus estimate of $3.10 million. Co-Diagnostics had a negative return on equity of 42.35% and a negative net margin of 582.36%. During the same quarter in the previous year, the firm earned ($0.20) EPS. Equities analysts expect that Co-Diagnostics will post -1.33 EPS for the current year.
Institutional Investors Weigh In On Co-Diagnostics
Co-Diagnostics Company Profile
Co-Diagnostics, Inc, a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. The company offers Co-Dx PCR platform, a polymerase chain reaction (PCR) testing to patients in point-of-care and at-home setting.
Featured Stories
- Five stocks we like better than Co-Diagnostics
- How to Find Undervalued Stocks
- How to Invest in Silver: A Beginner’s Guide
- Stock Average Calculator
- Monday.com’s Stock Results Will Brighten Any Investor’s Week
- Why Are These Companies Considered Blue Chips?
- 3 Must-Watch Stocks After a Bullish Goldman Sachs Recommendation
Receive News & Ratings for Co-Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Co-Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.